Industry
Medical - Devices
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Loading...
Open
6.15
Mkt cap
242M
Volume
100K
High
6.32
P/E Ratio
-4.16
52-wk high
14.84
Low
6.10
Div yield
N/A
52-wk low
5.46
Portfolio Pulse from
November 21, 2024 | 4:15 pm
Portfolio Pulse from
November 20, 2024 | 9:15 pm
Portfolio Pulse from
November 05, 2024 | 9:30 pm
Portfolio Pulse from
November 05, 2024 | 4:15 pm
Portfolio Pulse from Benzinga Newsdesk
October 31, 2024 | 5:58 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 9:28 pm
Portfolio Pulse from Benzinga Newsdesk
October 30, 2024 | 8:35 pm
Portfolio Pulse from Benzinga Insights
October 29, 2024 | 4:01 pm
Portfolio Pulse from Benzinga Newsdesk
September 09, 2024 | 8:25 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 5:17 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.